This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: YM Bio, Exact, Peregrine

"We have low conviction CYT387 anemia data will different from prior results, which showed no clinically relevant anemia benefit," McMinn said in a preview of the data this week.

2. Is CYT387 safe? For reasons still unclear and confusing (at least to me), a 28% rate of grade 1 (mild) peripheral neuropathy emerged as a worrisome issue for investors when the CYT387 data were last presented. More significantly, thrombocytopenia (low platelet counts) was reported by 42% of patients, including 22% grade 3 and 5% grade 4. It should be noted that YM Bio allowed patients with platelet counts as low as 50,000 to be enrolled in the CYT387 study, while Incyte excluded patients with platelet counts below 100,000.

3. Can CYT397 shrink spleens? Last spring's data demonstrated a 46% spleen response in 52 evaluable patients with a median response duration of 7.7 months. Sixty-two percent of patients achieved more than a 50% maximal decrease in spleen size from baseline; 92% achieved more than a 25% decrease in maximal spleen size.

Significant spleen shrinkage plus improvement in constitutional symptoms is what Incyte used to get Jakafi approved.


@oncobull tweets, "@adamfeuerstein, hey adam, what's up with YMI? acting like a dog ... but its mkt cap is soooo low. ... what's your bet for Monday ASH?"

The only bet I'd make with confidence is that Monday night's data presentation will be controversial. Any flaw in the data will be magnified; positive data will be marginalized. I realize that's a pessimistic view for a drug and a stock for which I have some hope and optimism, but it's a prudent mindset given the way YM Bio traded after last spring's ASCO presentation. I do believe that forced hedge fund selling remains the most logical explanation for the more recent weakness in the stock, but we're not exactly seeing many buyers step in either.

YM Bio has a dodgy reputation, mostly deserved, for developing bad drugs in the past so I'm not surprised that investors, generally speaking, mistrust the CYT387 data to date. I'm hoping this time around is different.


Dapo A. writes, "Adam, what does the Exact Sciences (EXAS - Get Report) announcement of Dec. 5, selling more shares, mean?"

Exact sold 3.125 million shares at $8, netting around $24 million. This is cushion money -- the company didn't really need it -- but it should give them enough cash to get through 2013 when, if all works well, the Cologuard colon-cancer screening test should be approved.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
EXAS $21.98 0.00%
INCY $107.34 0.00%
PPHM $1.38 0.00%
SPPI $6.10 0.00%
AAPL $130.28 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs